Aktienanalyse zu Teva Pharmaceutical Industries Limited.. (TEVA)TEVATeva Pharmaceutical Industries Limited..

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Teva Pharmaceutical is a good buy right now due to its recent FDA approval of Weltruza, which has the potential to significantly increase market share in the mental health sector. The current price is $41.50, and analysts have set a price target range between $50 and $55, indicating a potential upside of 20% to 32%. Additionally, the stock has shown strong momentum with a 1-year change of +113.70% and a 20-day change of +6.46%. However, the main risk is the recent insider selling, which has increased by 764.83%, suggesting potential concerns among insiders about the company's future performance.

26 analysts cover TEVA: 4 rate it Buy, 17 Hold and 5 Sell. The average price target is 35.71.